Monopar Therapeutics (MNPR) Debt Ratio (2020)

Monopar Therapeutics (MNPR) posted Debt Ratio of 0.01 for Q3 2020, down 29.49% sequentially from 0.01 in Q2 2020.

Monopar Therapeutics (MNPR) Debt Ratio (2020) Analysis & Trends

Monopar Therapeutics has reported Debt Ratio for 1 years, with the latest figure at 0.01 in Q3 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 0.05
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 0.12
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - 0.47
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 0.26
10 Monopar Therapeutics 965.64 Mn 912.88 Mn - -

Historic Data

Download Data
DateValue
Sep 30, 2020 0.01
Jun 30, 2020 0.01